MX2023015469A - Metodos y composiciones para estimular la actividad inmunitaria. - Google Patents

Metodos y composiciones para estimular la actividad inmunitaria.

Info

Publication number
MX2023015469A
MX2023015469A MX2023015469A MX2023015469A MX2023015469A MX 2023015469 A MX2023015469 A MX 2023015469A MX 2023015469 A MX2023015469 A MX 2023015469A MX 2023015469 A MX2023015469 A MX 2023015469A MX 2023015469 A MX2023015469 A MX 2023015469A
Authority
MX
Mexico
Prior art keywords
antigen binding
compositions
methods
binds
binding domain
Prior art date
Application number
MX2023015469A
Other languages
English (en)
Spanish (es)
Inventor
Patrick Schlegel
Alexander Joechner
Original Assignee
Biosceptre Aust Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021902832A external-priority patent/AU2021902832A0/en
Application filed by Biosceptre Aust Pty Ltd filed Critical Biosceptre Aust Pty Ltd
Publication of MX2023015469A publication Critical patent/MX2023015469A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
MX2023015469A 2021-09-01 2022-09-01 Metodos y composiciones para estimular la actividad inmunitaria. MX2023015469A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2021902832A AU2021902832A0 (en) 2021-09-01 Methods and compositions for stimulating immune activity
PCT/AU2022/051070 WO2023028657A1 (en) 2021-09-01 2022-09-01 Methods and compositions for stimulating immune activity

Publications (1)

Publication Number Publication Date
MX2023015469A true MX2023015469A (es) 2024-01-19

Family

ID=85410590

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2023015469A MX2023015469A (es) 2021-09-01 2022-09-01 Metodos y composiciones para estimular la actividad inmunitaria.
MX2023015028A MX2023015028A (es) 2021-09-01 2022-09-01 Nuevos aglutinantes del p2x7 disfuncional.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023015028A MX2023015028A (es) 2021-09-01 2022-09-01 Nuevos aglutinantes del p2x7 disfuncional.

Country Status (8)

Country Link
US (2) US20240368282A1 (enExample)
EP (2) EP4395814A4 (enExample)
JP (2) JP2024532482A (enExample)
CN (2) CN117813109A (enExample)
AU (2) AU2022341030A1 (enExample)
CA (2) CA3223079A1 (enExample)
MX (2) MX2023015469A (enExample)
WO (2) WO2023028657A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016100232A1 (en) * 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
CA3195512A1 (en) * 2020-10-14 2022-04-21 Vahe Bedian Compositions and methods for treatment of thyroid eye disease
JP2024531151A (ja) 2021-08-10 2024-08-29 ビリジアン セラピューティクス， インコーポレイテッド 甲状腺眼疾患の処置のための組成物、用量および方法
JP2026507807A (ja) * 2023-03-08 2026-03-06 バイオセプター （オースト） プロプライエタリー・リミテッド 機能不全ｐ２ｘ７受容体に結合するためのキメラ抗原受容体
WO2024211413A2 (en) * 2023-04-05 2024-10-10 Arizona Board Of Regents On Behalf Of The University Of Arizona Trogocytosis in cancer cells and methods for treating cancer related thereto
WO2024220870A1 (en) * 2023-04-19 2024-10-24 The University Of Chicago Antibody-targeted enzymatic chemoprotection
KR20260024373A (ko) * 2023-05-05 2026-02-20 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 다중-수용체 자연 살해 세포
WO2025000037A1 (en) * 2023-06-30 2025-01-02 Biosceptre (Aust) Pty Ltd Molecules and methods for activating car t cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3395832B1 (en) * 2009-08-20 2021-11-24 Biosceptre (Aust) Pty Ltd Anti p2x7 receptor antibodies and fragments thereof
EP2516470B1 (en) * 2009-12-24 2018-02-07 Biosceptre (Aust) Pty Ltd Antibodies to non-functional oligomeric p2x7 receptors
CN107614528A (zh) * 2015-04-02 2018-01-19 生物权威（英国）有限公司 疼痛治疗
US12121539B2 (en) * 2015-09-11 2024-10-22 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors and uses thereof
CN109862883A (zh) * 2016-10-21 2019-06-07 生物权威（英国）有限公司 细胞毒性颗粒
AU2019275479B2 (en) * 2018-05-21 2022-12-08 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors with modified linker domains and uses thereof
WO2020191344A1 (en) * 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
MX2021011750A (es) * 2019-03-27 2021-12-10 Nat Res Council Canada Anticuerpos anti-egfrviii y fragmentos de union a antigenos de los mismos.
CA3211323A1 (en) * 2021-03-11 2022-09-15 Patrick Schlegel Novel cell therapy system

Also Published As

Publication number Publication date
EP4395814A4 (en) 2025-09-03
WO2023028657A1 (en) 2023-03-09
CN117813109A (zh) 2024-04-02
AU2022335932A1 (en) 2023-11-30
MX2023015028A (es) 2024-02-16
US20240368282A1 (en) 2024-11-07
EP4395814A1 (en) 2024-07-10
JP2024532482A (ja) 2024-09-05
WO2023028653A1 (en) 2023-03-09
JP2024532489A (ja) 2024-09-05
US20240376193A1 (en) 2024-11-14
EP4395813A1 (en) 2024-07-10
AU2022341030A1 (en) 2023-11-30
EP4395813A4 (en) 2025-07-09
CA3223086A1 (en) 2023-03-09
CN117881421A (zh) 2024-04-12
CA3223079A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
JOP20210289A1 (ar) مقترنات عقار - جسم مضاد مثبط لـmcl-1 وطرق لاستخدامها
EA202090372A1 (ru) Универсальные соединения авт и их применение
IL311603B1 (en) Bispecific antibodies and compounds containing them for cancer treatment
WO2021227307A8 (zh) 抗cd73抗体及其用途
BR112022002579A2 (pt) Anticorpos contra ilt2 e uso dos mesmos
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
MY189159A (en) Multispecific antigen-binding molecules and uses thereof
BR112018015238A2 (pt) conjugado de anticorpo, anticorpo, kit, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição e para diagnosticar uma doença ou condição
BR112022026236A2 (pt) Terapia de combinação de imuno-oncologia com conjugados de il-2 e anticorpos anti-egfr
MX2022003005A (es) Composiciones y metodos de anticuerpos anti-cd39.
MX2023014069A (es) Composiciones y métodos para el tratamiento del cáncer de próstata.
BR112015000776A2 (pt) Agentes de ligação à rspo3 e usos dos mesmos
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
BR112022024501A2 (pt) Construtos de rnai para inibir a expressão de hsd17b13 e métodos de uso dos mesmos
WO2022082073A3 (en) Compositions and methods for muc18 targeting
MX2022014995A (es) Metodos de tratamiento de la nefropatia por iga con un anticuerpo de union a april.
MX2022013876A (es) Constructos de anticuerpos triespecificos precursores y metodos de uso de los mismos.
BR112022018254A2 (pt) Anticorpos isolados, ácido nucleico isolado, vetor ou conjunto de vetores, célula hospedeira, métodos para produzir um anticorpo, para tratar um distúrbio e para tratar ag em um paciente, composição e uso de um anticorpo
EA202092518A1 (ru) Композиции и способы лечения рака
WO2023201234A3 (en) Anti-variable muc1* antibodies and uses thereof
MX2022011050A (es) Anticuerpos anti-cd36 y su uso para tratar cancer.
MX2021015501A (es) Anticuerpos y metodos de uso.
EA202192757A1 (ru) Способ лечения опухолей
WO2021003050A3 (en) Cd38-binding agents and uses thereof
AR131398A1 (es) Tratamiento de enfermedades autoinmunitarias